Exhibit 99.1 MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update 2022 total revenues of 26.5millionFDAapprovalofNexoBridR◯inDecember2022;U.S.commercialavailabilityexpectedinthesecondquarterof2023EscharExR◯PhaseIIIprotocoldesignisunderreviewbytheFDA;studytobeinitiatedinthesecondhalfof2023Cashpositionof66 million, including cash received for the NexoBrid approval milestone and recent equity financing Conference call begins today a ...